Common Infections in the Lung Transplant Recipient

Clinics in Chest Medicine

Volumn 32, Issue 2, 2011, Pages 327-341

  Sims, Karen D ^a   Blumberg, Emily A ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fungal infection; Gram negative bacterial infection; Infection; Lung transplant; Mycobacteria; Prophylaxis; Respiratory virus

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; FLUCONAZOLE; GANCICLOVIR; OSELTAMIVIR; PLACEBO; RIBAVIRIN; VALGANCICLOVIR; VORICONAZOLE; ZANAMIVIR;

ASPERGILLOSIS; BACTERIAL INFECTION; CANDIDIASIS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG MEGADOSE; GRAFT RECIPIENT; HEMOLYTIC ANEMIA; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INVASIVE ASPERGILLOSIS; LUNG INFECTION; LUNG TRANSPLANTATION; NEUROMUSCULAR DISEASE; PARAMYXOVIRUS INFECTION; PERIOSTITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; REVIEW; SCREENING TEST;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFLUENZA, HUMAN; LUNG TRANSPLANTATION; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; RESPIRATORY TRACT INFECTIONS;

EID: 79954602231     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.02.010     Document Type: Review

References (104)

1. Christie J.D., Edwards L.B., Kucheryavaya A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010, 29(10):1104-1118.
2. Kotloff R.M., Ahya V.N., Crawford S.W. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004, 170(1):22-48.
3. Kotloff R.M., Ahya V.N. Medical complications of lung transplantation. Eur Respir J 2004, 23(2):334-342.
4. Remund K.F., Best M., Egan J.J. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009, 6(1):94-100.
5. Fischer S.A., Avery R.K. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009, 9(SUPPL 4):S7-S18.
6. Danzinger-Isakov L., Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009, 9(SUPPL 4):S258-S262.
7. Subramanian A., Dorman S. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S57-S62.
8. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007, 357(25):2601-2614.
9. Aguilar-Guisado M., Givaldá J., Ussetti P., et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 2007, 7(8):1989-1996.
10. Humar A., Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S78-S86.
11. Eid A.J., Razonable R.R. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70(8):965-981.
12. Humar A., Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006, 6(2):262-274.
13. Rubin R.H. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'. Curr Opin Infect Dis 2007, 20(4):399-407.
14. Glanville A.R., Valentine V.G., Aboyoun C.L., et al. CMV mismatch is not a risk factor for survival or severe bronchiolitis obliterans syndrome after lung transplantation. Immunol Cell Biol 2004, 82(2):A7.
15. Chmiel C., Speich R., Hofer M., et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008, 46(6):831-839.
16. Manuel O., Kumar D., Moussa G., et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009, 87(5):719-725.
17. Johanssson I., Martensson G., Andersson R. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden. Scand J Infect Dis 2010, 42(2):129-136.
18. Ruttmann E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006, 81(10):1415-1420.
19. Tamm M., Aboyoun C.L., Chhajed P.N., et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004, 170(10):1120-1123.
20. Snyder L.D., Finlen-Copeland C.A., Turbyfill W.J., et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010, 181(12):1391-1396.
21. Pang X.L., Fox J.D., Fenton J.M., et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9(2):258-268.
22. Kumar D., Chernenko S., Moussa G., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009, 9(5):1214-1222.
23. Kotton C.N., Kumar D., Caliendo A.M., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89(7):779-795.
24. Hodson E.M., Craig J.C., Strippoli G.F., et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008, 2. CD003774.
25. Zamora M.R. Cytomegalovirus and lung transplantation. Am J Transplant 2004, 4(8):1219-1226.
26. Zamora M.R., Nicolls M.R., Hodges T.N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004, 4(10):1635-1642.
27. Valentine V.G., Weill D., Gupta M.R., et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008, 27(8):875-881.
28. Palmer S.M., Limaye A.P., Banks M., et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010, 152(12):761-769.
29. Kelly J., Hurley D., Raghu G. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 2000, 19(4):355-359.
30. Limaye A.P., Raghu G., Koelle D.M., et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002, 185(1):20-27.
31. Monforte V., Román A., Gavaldà J., et al. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Transplant Proc 2005, 37(9):4039-4042.
32. Asberg A., Humar A., Rollag H., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7(9):2106-2113.
33. Asberg A., Humar A., Jardine A.G., et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009, 9(5):1205-1213.
34. Mylonakis E., Kallas W.M., Fishman J.A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002, 34(10):1337-1341.
35. Kumar D., Husain S., Chen M.H., et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010, 89(8):1028-1033.
36. Billings J.L., Hertz M.I., Savik K., et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002, 21(5):559-566.
37. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004, 170(2):181-187.
38. Kumar D., Erdman D., Keshavjee S., et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005, 5(8):2031-2036.
39. Milstone A.P., Brumble L.M., Barnes J., et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006, 28(1):131-137.
40. Ison M.G., Michaels M.G. RNA respiratory viral infections in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S166-S172.
41. Kumar D., Morris M.I., Kotton C.N., et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010, 10(1):18-25.
42. Boeckh M., Englund J., Li Y., et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007, 44(2):245-249.
43. Glanville A.R., Scott A.I., Morton J.M., et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005, 24(12):2114-2119.
44. Pelaez A., Lyon G.M., Force S.D., et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009, 28(1):67-71.
45. Campos S., Caramori M., Teixeira R., et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc 2008, 40(3):822-824.
46. Valentine V.G., Bonvillain R.W., Gupta M.R., et al. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant 2008, 27(5):528-535.
47. Dobbin C., Maley M., Harkness J., et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004, 56(4):277-282.
48. Hadjiliadis D., Steele M.P., Chaparro C., et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007, 26(8):834-838.
49. Lynch J.P. Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin Respir Crit Care Med 2009, 30(5):596-610.
50. Alexander B.D., Petzold E.W., Reller L.B., et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008, 8(5):1025-1030.
51. Boussaud V., Guillemain R., Grenet D., et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008, 63(8):732-737.
52. Murray S., Charbeneau J., Marshall B.C., et al. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008, 178(4):363-371.
53. Orens J.B., Boehler A., de Perrot M., et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003, 22(11):1183-1200.
54. Avlonitis V.S., Krause A., Luzzi L., et al. Bacterial colonization of the donor lower airways is a predictor of poor outcome in lung transplantation. Eur J Cardiothorac Surg 2003, 24(4):601-607.
55. Weill D., Dey G.C., Hicks R.A., et al. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant 2002, 21(5):555-558.
56. Bonde P.N., Patel N.D., Borja M.C., et al. Impact of donor lung organisms on post-lung transplant pneumonia. J Heart Lung Transplant 2006, 25(1):99-105.
57. Vos R., Vanaudenaerde B.M., Geudens N., et al. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation?. Eur Respir J 2008, 31(5):1037-1045.
58. Gottlieb J., Mattner F., Weissbrodt H., et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009, 103(5):743-749.
59. Botha P., Archer L., Anderson R.L., et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008, 85(5):771-774.
60. Vos R., Blondeau K., Vanaudenaerde B.M., et al. Airway colonization and gastric aspiration after lung transplantation: do birds of a feather flock together?. J Heart Lung Transplant 2008, 27(8):843-849.
61. Malouf M.A., Glanville A.R. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1611-1616.
62. Kesten S., Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999, 115(3):741-745.
63. Chalermskulrat W., Sood N., Neuringer I.P., et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006, 61(6):507-513.
64. Sanguinetti M., Ardito F., Fiscarelli E., et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001, 39(2):816-819.
65. Fairhurst R.M., Kubak B.M., Shpiner R.B., et al. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002, 21(3):391-394.
66. Taylor J.L., Palmer S.M. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006, 25(8):985-988.
67. Gilljam M., Scherstén H., Silverborn M., et al. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010, 9(4):272-276.
68. Zaidi S., Elidemir O., Heinle J.S., et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009, 11(3):243-248.
69. Chernenko S.M., Humar A., Hutcheon M., et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006, 25(12):1447-1455.
70. Garrison A.P., Morris M.I., Doblecki L.S., et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009, 11(6):541-548.
71. Longworth S.A., Vinnard C., Lee I., et al. Risk factors for non-tuberculous mycobacterial infections in heart and lung transplant recipients. J Heart Lung Transplant 2010, 29(2S):S82.
72. Doucette K., Fishman J.A. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004, 38(10):1428-1439.
73. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
74. Dorman S., Subramanian A. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S63-S69.
75. Kubak B.M. Fungal infection in lung transplantation. Transpl Infect Dis 2002, 4(Suppl 3):24-31.
76. Sole A., Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med 2009, 15(3):243-253.
77. Proia L., Miller R. Endemic fungal infections in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S199-S207.
78. Singh N., Forrest G. Cryptococcosis in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S192-S198.
79. Sole A., Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando) 2008, 22(2):89-104.
80. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000, 31(2):545-553.
81. Neofytos D., Fishman J.A., Horn D., et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010, 12(3):220-229.
82. Pappas P.G., Alexander B.D., Andes D.R., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010, 50(8):1101-1111.
83. Helmi M., Lover R.B., Welter D., et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003, 123(3):800-808.
84. Mehrad B., Paciocco G., Martinez F.J., et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001, 119(1):169-175.
85. Vadnerkar A., Clancy C.J., Celik U., et al. Impact of mold infections in explanted lungs on outcomes of lung transplantation. Transplantation 2010, 89(2):253-260.
86. Cahill B.C., Hibbs J.R., Savik K., et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997, 112(5):1160-1164.
87. Husain S., Kwak E.J., Obman A., et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004, 4(5):796-802.
88. Clancy C.J., Jaber R.A., Leather H.L., et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007, 45(6):1759-1765.
89. Husain S., Paterson D.L., Studer S.M., et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007, 83(10):1330-1336.
90. Wheat L.J. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 2009, 30(2):367-377. viii.
91. Wengenack N.L., Binnicker M.J. Fungal molecular diagnostics. Clin Chest Med 2009, 30(2):391-408. viii.
92. Hosseini-Moghaddam S.M., Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010, 31(2):222-233.
93. Husain S., Paterson D.L., Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006, 6(12):3008-3016.
94. Boussaud V., Daudet N., Billaud E.M., et al. Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus. J Heart Lung Transplant 2008, 27(2):229-232.
95. Wang T.F., Wang T., Altman R., et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009, 9(12):2845-2850.
96. Thomas L.D., Miller G.G. Interactions between antiinfective agents and immunosuppressants. Am J Transplant 2009, 9(SUPPL 4):S263-S266.
97. Singh N., Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S180-S191.
98. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3):327-360.
99. Morales P., Galán G., Sanmartín E., et al. Intrabronchial instillation of amphotericin B lipid complex: a case report. Transplant Proc 2009, 41(6):2223-2224.
100. Berge M., Guillemain R., Boussaud V., et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009, 11(3):211-219.
101. Howard A., Hoffman J., Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008, 42(12):1859-1864.
102. Armstrong-James D., Teo I.A., Shrivastava S., et al. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant 2010, 10(8):1796-1803.
103. Pappas P.G., Silveira F.P. Candida in solid organ transplant recipients. Am J Transplant 2009, 9(SUPPL 4):S173-S179.
104. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.